Attendee search 

GU Holding is a company owned by the Swedish government. Its mission is to provide funds and business competence for new companies to ensure growth of value and development of companies based on top-notch academic competence and research within University of Gothenburg.

The business concept consists of supplying project and start-up capital together with business competency to add value to and efficiently develop new businesses based on academic leading edge competency and research results. The aim is to create successful growth companies. All projects must be commercially viable, and business ideas and inventions must meet high standards.

GU Holding's mission is to contribute to the development of University of Gothenburg, its staff as well as the whole of the Västra Götaland region. There is close cooperation between the university, including all pursued disciplines, and its various bodies dealing with commercialisation, such as GU Research and Innovation Services.

GU Holding works together with Research and innovationservice at University of Gothenburg. Further, GU Holding has close contact with other innovation actors, such as The Innovation Bridge, Sahlgrenska Science Park, Vinnova, Innovationskontor Väst, Västra Götaland Region and Tillväxtverket as well as business entrepreneurs, private actors within trade and industry or on the capital market, for instance highly esteemed venture capitalists.

The portfolio of GU Holding consists of 33 newly build companies and 14 business projects in many different areas.

GU Holding has invested in pain relief, speaking computers, customized back-in counters, security, oyster farming, a cure for kidney cancer and fish feed ingredient to name a few.

TATAA Biocenter is Europe’s leading provider of gene expression profiling services and a prime organizer of hands-on training in quantitative real-time PCR (qPCR).

Frost & Sullivan presents TATAA Biocenter with the 2013 European Frost & Sullivan Award for customer value leadership.

TATAA is one of the first laboratories to have obtained ISO/IEC 17025:2005 flexible certification for qPCR analysis in Europe. 

Forskarpatent specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. At present Forskarpatent holds a portfolio of 15 different projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets.

Company: LipUm AB, Umeå, Sweden (Susanne Lindquist, Olle Hernell and Lennart Lundberg)

 LipUm AB´s goal is to develop a novel biological anti-inflammatory therapy with the protein BSSL (Bile Salt-Stimulated Lipase) as target.

PressCise is a research project from CHalmers and University of Gothenburg aimed at developing a unique bandage. The bandage will be used for remediation including varicose vein surgery and should be easy to wrap.

ClinTrials Skåne is a public limited company dedicated to helping the life science industry developing their products in close cooperation with universities and the public health care sector in the county of Skåne. We have long experience in working with clinical trials and product development in hospitals in Skåne. Our offices are located in Skåne university hospital and in Medicon Village in Lund, with direct access to both the life science industry and the public healthcare system.

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes three product candidates for the treatment of cancer.

Our mission is to generate value for shareholders by building a sustainable portfolio of clinical development projects and, over time, successfully launching several innovative drugs.

In order to maximise the value of the Company we plan to:

• Commercialise product candidates in co-operation with partners.
• Retain rights to individual geographic markets for particular products where we consider that it would be feasible to establish a competitive sales and marketing force.
• Broaden and expand our product portfolio to create more opportunities for generating successful products and increasing the likelihood of commercial success for the Company as a whole.
• Gain access to innovative target proteins and/or projects from external research groups and use these as a basis for generating novel therapeutics using our proprietary technology platform.

Our revenues include licence fees, milestone payments, compensation of manufacturing and royalties on sales derived from our co-operation agreements around our product candidates. We also generate income by providing discovery development to our customers.

We expect to achieve sustainable profitability as soon as one of our products reaches the market. However, profits may be reported in certain years before this as projects reach key milestones that trigger payments from partners.